Page last updated: 2024-11-03

rabeprazole and Myelodysplastic Syndromes

rabeprazole has been researched along with Myelodysplastic Syndromes in 1 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yasu, T1
Konuma, T1
Kato, S1
Kurokawa, Y1
Takahashi, S1
Tojo, A1

Other Studies

1 other study available for rabeprazole and Myelodysplastic Syndromes

ArticleYear
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Annals of hematology, 2016, Volume: 95, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Body Weight; Bone Marrow Transplan

2016